The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public health alert.
NAFDAC warns Nigerians against the use of Acetazolamide Tablets USP 125mg due to safety concerns. The tablets are manufactured by Rubicon Research Private Ltd, an American pharmaceutical company. The affected batch, 30575HF1, has been recalled due to contamination and discoloration. This recall affects the lot manufactured in December 2023 and has an expiry date of November 2026.
Acetazolamide is a diuretic used to treat fluid retention, glaucoma, and certain convulsive disorders like epilepsy. It works by promoting urine production, helping remove excess salt and water from the body. The contaminated tablets may lead to serious health risks, including poisoning, treatment failure, and compromised drug effectiveness. Consumers are urged to avoid using the affected batch immediately.
NAFDAC has advised healthcare professionals, importers, and distributors to be cautious of the affected product within the supply chain. The agency emphasizes the importance of verifying product authenticity and physical condition before use or sale. Anyone in possession of the recalled tablets is urged to return them to the nearest NAFDAC office.
The alert was posted on NAFDAC’s official website, highlighting the agency’s ongoing efforts to inform the public about unsafe medical products. Consumers who have used the affected product or experienced adverse reactions should seek immediate medical attention. Healthcare professionals and patients are encouraged to report any side effects related to the drug. Reports can be made via NAFDAC’s e-reporting platforms on their website or the Med-Safety application.
NAFDAC urges the public to ensure that all medicines are purchased from authorized and licensed suppliers. The agency continues to monitor the situation closely and reassures the public of its commitment to health safety.
